Drug Type Immune cell therapy |
Synonyms |
Target |
Mechanism EIF2AK4 modulators(eukaryotic translation initiation factor 2 alpha kinase 4 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune System Diseases | Preclinical | US | 23 Jan 2024 | |
Neoplasms | Preclinical | US | 23 Jan 2024 |